Global Health Community Says The U.S. Is Picking Big Business Over Patients Again

The global health community has once again found itself in a familiar position: fighting the U.S. on a policy previously seen as a no-brainer. The fight against tuberculosis, the world’s top infectious killer, has been consuming United Nations negotiators for the last two months as they prepare for the first U.N.

Read More

Paracetamol sales rising but firms’ revenue suffers due to price cuts

Related News Six out of top 10 brands of paracetamol in India – Calpol, Sumo L, P-250, Crocin, Tamin and Fepanil – have registered a fall in annual sales growth in value terms in 2017-18. However, their annual sales in unit terms have comparatively increased in the same period, indicating a price reduction across brands.

Read More

How A Drugmaker Gamed The System To Keep Generic Competition Away

Updated 11:16 EDT: This story now includes information about the Food and Drug Administration’s release of a list of complaints against brand-name drugmakers for hindering access to samples for generic testing. When Celgene Corp. first started marketing the drug Revlimid to treat multiple myeloma in 2006, the price was $6,195 for 21 capsules, a month’s supply.

Read More

Trump directs USTR to take up pricing of pharmaceuticals, medical devices

President Donald Trump today directed his top trade negotiator to strongly take up with all countries the fixing of prices of American pharmaceuticals and medical devices. Describing such fixing of prices by other countries as unjustified and done at the expense of America’s research and development, Trump said that the US can longer tolerate such behaviour by others.

Read More

The Best Fix for Drug Prices Is Already on the Books

The Drug Price Competition and Patent Term Restoration Act – better known as Hatch-Waxman – was signed into law by President Ronald Reagan 34 years ago. Sponsored by Senator Orrin Hatch of Utah, a devout conservative, and Representative Henry Waxman of California, a flaming liberal, its primary purpose was to make drugs more affordable by kick-starting the relatively new generic drug industry.

Read More

Trump: Other nations extort drug-makers

US President Donald Trump has accused foreign governments of extorting “unreasonably low prices” from pharmaceutical firms. Speaking in Washington on Friday, he said he had directed his top trade negotiator to make the issue a priority in trade talks. “It is time to end the global freeloading once and for all,” he said.

Read More

President Donald J. Trump’s Blueprint To Lower Drug Prices

One of my greatest priorities is to reduce the price of prescription drugs. A BURDEN ON THE AMERICAN PEOPLE: Drug prices are being driven up unfairly, taking a toll on the American people. Excessively high drug prices, foreign freeloading, and a system rigged to reward list price increases, are burdening the American people.

Read More

A Supreme Court victory for lowering drug prices

A recent Supreme Court decision on patents – Oil States v. Greene’s Energy Group marks an understated victory, with far-reaching consequences that will positively impact families and communities across America. This case has deep implications for basic economic fairness, with the judiciary recognizing the importance of keeping critical checks in systems that have become far too imbalanced.

Read More

Why do new medicines cost so much, and what can we do about it?

Why does it matter what medicines cost? If you are lucky enough to live in a country with comprehensive state-funded healthcare, such as the UK, you probably have no idea how much medicines really cost. But it can be a lot. Some drugs that have been around for ages are very cheap – aspirin, for instance, costs pence.

Read More

WHO launches plan for cheaper TB drugs

The World Health Organisation (WHO), on Tuesday, invited pharmaceutical companies around the world to submit proposals to manufacture affordable versions of newer medicines for treatment of drug resistant tuberculosis. A WHO spokesman said the aim was to replicate the success of addressing the HIV epidemic.

Read More

Last chance for medical devices firms to submit price data: NPPA – Times of India

New Delhi, Mar 4 () National drug pricing regulator NPPA has said medical devices makers and importers are being given the last opportunity to submit data regarding price movement of 19 medical devices notified as drugs by March 15, 2018.

Read More

Drug pricing: A regulatory tug of war

The pharmaceutical industry has suggested to the central government that it should increase its reviewing powers on the decisions taken by National Pharmaceutical Pricing Authority (NPPA). The regulator is learnt to have responded with a contrarian view that the government should “abandon its archaic practice of reviewing NPPA orders” and, instead, establish an independent appellate tribunal.

Read More

4 NCR hospitals jacked up prices of branded drugs 12 fold: NPPA

Some hospitals in the National Capital Region (NCR) prescribed branded medicines that were outside the regulator’s purview and inflated their prices several times in order to boost profit, the National Pharmaceutical Pricing Authority said. Four hospitals in the NCR marked up the retail prices of such medicines as much as 12-fold from the rates at which they were purchased, NPPA said in a report.

Read More

NPPA analysis: Three private hospitals earn huge margins on drugs

National Pharmaceutical Pricing Authority (NPPA) on Tuesday came out with a price analysis of three unnamed private hospitals in the city that showed huge margins on MRPs kept by these hospitals on drugs and consumables, ranging from 2112 per cent to 116 per cent.

Read More

Cardiac stent price cap lowered further to Rs 28,000 – Times of India

The National Pharmaceutical Pricing Authority on Monday revised the price of drug eluting stents (DES) downwards by about Rs 2,300 to just under Rs 28,000, while marginally raising the cap on bare metal stents from Rs 7,400 to Rs 7,660. These caps are excluding GST.

Read More